Dysfunction Treatment via Pharmacy Network Rollout
20 May 2025 – Sydney, Australia | LTR Pharma has announced the expansion of patient access to its fast-acting erectile dysfunction (ED) treatment, SPONTAN®, via a nationwide rollout through pharmacies dispensing under the TGA’s Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS). SPONTAN® will now be available at over 600 pharmacies across Australia, distributing via the TerryWhite Chemmart network, alongside Pharmacy Choice and healthSAVE.
The milestone marks the commercial implementation of LTR Pharma’s national distribution partnership with Symbion and enhances physical access for patients with prescriptions from authorised healthcare professionals.
Highlights:
-
SPONTAN® will now be available via TerryWhite Chemmart’s national pharmacy network of over 600 pharmacies.
-
Commercial packaging, including a TGA-compliant barcode, has been introduced to support pharmacy integration and for future telehealth pathways.
-
Dispensing is supported by trained pharmacists and operates under SAS and APS.
-
The rollout enables real-world data collection on prescribing patterns and patient experience to inform future regulatory submissions in Australia and the planned 2026 US launch of ROXUS®.
Commenting on the development, LTR Pharma Executive Chairman, Lee Rodne, said: "The national rollout of SPONTAN through TerryWhite Chemmart and other pharmacy networks represents the implementation of our Symbion partnership and delivers convenient physical access points for patients across the country. This milestone supports our commitment to improving the availability of SPONTAN across Australia while we progress our regulatory pathway. Patients can now have their SPONTAN prescriptions filled at participating pharmacies nationwide, providing a direct pathway from healthcare professional to pharmacy dispensing."
Media Enquiries:
Haley Chartres
[email protected]
Investor Enquiries:
Peter McLennan
[email protected]
About us:
About LTR Pharma Limited (ASX:LTP)
LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas.
LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
